Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diagnostic testing for hepatitis C: practical considerations.

M W Fried1

  • 1University of North Carolina at Chapel Hill, Division of Digestive Diseases, 27599-7080, USA.

The American Journal of Medicine
|February 1, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy.

Alimentary pharmacology & therapeutics·2018
Same author

Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders.

Haemophilia : the official journal of the World Federation of Hemophilia·2017
Same author

All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database.

Alimentary pharmacology & therapeutics·2016
Same author

Plasma levels of growth-related oncogene (CXCL1-3) associated with fibrosis and platelet counts in HCV-infected patients.

Alimentary pharmacology & therapeutics·2015
Same author

Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir.

Alimentary pharmacology & therapeutics·2015
Same author

Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies.

Journal of viral hepatitis·2014
Same journal

Mineralocorticoid Antagonists for Post-MI HFpEF: Plausible Biology Meets Low Residual Risk?

The American journal of medicine·2026
Same journal

GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

The American journal of medicine·2026
Same journal

Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

The American journal of medicine·2026
Same journal

Cave Canem - Beware of the Dog.

The American journal of medicine·2026
Same journal

Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

The American journal of medicine·2026
Same journal

Mesenteric panniculitis.

The American journal of medicine·2026
See all related articles

Hepatitis C virus (HCV) genotyping and quantitation offer insights into disease progression and treatment response. Tailoring therapy based on these virologic variables can optimize patient outcomes and reduce unnecessary treatments.

Area of Science:

  • Hepatology
  • Virology
  • Molecular Biology

Background:

  • Current therapies for chronic hepatitis C remain suboptimal.
  • Understanding hepatitis C virus (HCV) molecular biology is advancing rapidly.
  • Virologic variables are being explored to personalize treatment strategies.

Purpose of the Study:

  • To evaluate the clinical utility of hepatitis C virus RNA levels and genotyping.
  • To develop a rational plan for cost-effective use of diagnostic tests.
  • To guide clinical decision-making for individual patient treatment.

Main Methods:

  • Retrospective analysis of studies involving HCV genotyping and viral burden.
  • Assessment of the role of virologic variables in disease progression and treatment response.

Related Experiment Videos

  • Evaluation of the widespread availability and application of diagnostic tests.

    • Main Results:

    • HCV genotyping and viral burden show potential roles in disease progression.
    • These virologic markers may influence patient response to therapy.
    • The utility of these tests in daily clinical practice is still evolving.

    Conclusions:

    • Genotyping and quantitation of hepatitis C virus provide valuable insights.
    • Tailoring therapy based on virologic variables can improve treatment efficacy.
    • Further research is needed to refine the use of these tests in clinical decision-making.